



→ **OMPs IN THE EU AND SPAIN**





→ **MAY-AUGUST 2024**




→ **OMPs REIMBURSED IN SPAIN**

May-August 2024
OMPs REIMBURSED BY THERAPEUTIC AREA




→ **% REIMBURSED**

OMPs WITH MARKETING AUTHORISATION REIMBURSED BY THE NHS 2020 - 2024




OMPs WITH NC REIMBURSED BY THE NHS 2020 - 2024




→ **AVERAGE WAITING TIME**


MONTHS BETWEEN NC AND INCORPORATION INTO THE NHS




→ **OMPs NOT REIMBURSED IN SPAIN**



NUMBER OF OMPs NOT REIMBURSED BY YEAR OF NC




NUMBER OF OMPs NOT REIMBURSED BY THERAPEUTIC AREA




→ **OMPs WITH MA PENDING TO ARRIVE IN SPAIN**




→ **% OMPs WITH MA WITHOUT NC**




WAITING TIME SINCE MA




BY THERAPEUTIC AREA



→ **ADVANCED THERAPIES WITH ORPHAN DESIGNATION**



→ **ADVANCED THERAPIES WITH MA, NC AND REIMBURSING 2018-2024**



Note: for the preparation of this report it has not been possible to take into account drugs that are available in Spain under specific situations and special authorisations within the framework of Royal Decree 1015/2009 (compassionate use, use under conditions other than those authorised or access to foreign medicines), as the data were not available.
**The 16 Advanced Therapies with OD and MA would be included in the total of 208 MMH with OD and in the 149 MMH with MA, as they are TTAAs with trade name.